Analysis of the therapeutic effect of telisotuzumab-EMRELIS, clinical efficacy and patient experience

Telisotuzumab (trade name EMRELIS) is a new type of targeted therapy drug that mainly targets patients with c-Met overexpression tumors of the epidermal growth factor receptor family, including non-small cell lung cancer (NSCLC). c-MetAs an important signaling pathway for tumor cell proliferation, invasion and metastasis, it is extremely active in some patients with advanced NSCLC and therefore becomes an important direction for targeted therapy. EMRELISAs an anti-c-Metmonoclonal antibody drug conjugate (ADC< span>), through highly selective binding to c-Met receptors, cytotoxic drugs are directly delivered into tumor cells to achieve precise killing, thereby improving efficacy and reducing systemic toxic and side effects. It is an important breakthrough in the field of anti-lung cancer in recent years.

In clinical studies, EMRELIS has shown relatively ideal anti-tumor activity. In the II phase multicenter trial, for c-Methighly expressed late-stage NSCLCPatients, EMRELISmonotherapy can achieve a high objective response rate (ORR), and some patients experience significant tumor shrinkage or lesion regression. In addition, the median progression-free survival (PFS) is significantly prolonged. Compared with traditional chemotherapy and some targeted drugs, EMRELIS provides a new treatment option for patients with drug resistance or relapse. Clinical data shows that the drug is generally well tolerated. Common adverse reactions include mild fatigue, nausea, mild decrease in platelets, etc. Most of them can be controlled through symptomatic treatment or dose adjustment.

Real-world patient experience has further verified the clinical value of EMRELIS. Some patients who received treatment reported that EMRELIS had a significant effect in improving the quality of life, especially on symptom control and physical strength maintenance. Due to its strong targeting and relatively controllable side effects, patients can maintain their daily life and work while taking periodic outpatient medication. In addition, for patients who have previously failed multiple lines of chemotherapy or other targeted drug treatments, EMRELIS provides effective follow-up treatment options, allowing patients to extend progression-free survival and improve overall prognosis.

However, the use of EMRELIS still needs to be combined with individualized evaluation. First of all, it is necessary to clarify the patient's c-Met expression level. Only patients with c-Met high expression can benefit from the drug. Secondly, although the side effects are relatively controllable, the patient's liver and kidney function, blood picture, and comorbid diseases should be evaluated before receiving treatment to ensure safe medication. In addition, because the drug is not yet widely available in China, patients need to obtain it through clinical trials or overseas formal channels when using it. Cost and accessibility are still real challenges. In the future, with the accumulation of more clinical data and domestic marketing promotion, EMRELIS is expected to become an important treatment option for c-Metpositive late-stage NSCLC patients, providing more efficient and safer targeted treatment options for drug-resistant, relapsed or advanced patients, while improving patients' quality of life and overall prognosis.

Reference materials:https://www.drugs.com/